US Stock Insider Trading | Rhythm disclosed 4 insider trading transactions on February 6

K-LinePoet · 2026-03-07T02:15:03+00:00

On February 6, 2026, Rhythm Pharmaceuticals disclosed that its executive Smith Hunter C recently conducted multiple stock transactions. Including selling 3,381 shares on February 5, 2026, at a price of $106.06 per share, totaling $358,600. The company focuses on treating rare neuroendocrine diseases.

K-LinePoet

2026-03-07 02:15:03

Abstract generation in progress

On February 6, 2026, Rhythm (RYTM) disclosed four insider trading transactions. Executive Smith Hunter C sold 3,381 shares on February 5, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Executive	Smith Hunter C	February 5, 2026	Sell	3,381	106.06	358,600
February 6, 2026	Executive	Smith Hunter C	February 4, 2026	Sell	1,500	104.74	157,100
February 6, 2026	Executive	Smith Hunter C	February 4, 2026	Sell	1,000	106.60	106,600
February 6, 2026	Executive	Smith Hunter C	February 4, 2026	Sell	747	107.67	80,400
February 3, 2026	Executive	Smith Hunter C	February 1, 2026	Sell	10,800	108.99	1,171,600
February 3, 2026	Executive	Cramer Pamela J.	February 1, 2026	Sell	4,731	108.99	515,600
February 3, 2026	Executive	Garfield Alastair	February 1, 2026	Sell	2,026	108.99	220,800
February 3, 2026	Executive	Shulman Joseph	February 1, 2026	Sell	6,507	108.99	709,200
February 3, 2026	Executive	German Christopher Paul	February 1, 2026	Sell	1,138	108.99	124,000
February 3, 2026	Director	Meeker David P	February 1, 2026	Sell	31,500	108.99	3,435,600

[Company Information]

Rhythm Pharmaceuticals, Inc. is a Delaware corporation founded in February 2013. The company is a global, commercial-stage biopharmaceutical company dedicated to changing the lives of patients and their families affected by rare neuroendocrine diseases. The company focuses on advancing melanocortin-4 receptor (MC4R) agonists, including their lead asset IMCIVREE, as targeted therapies designed to treat hyperphagia and severe obesity caused by rare MC4R pathway disorders.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes